Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study

Frederick R. Singer; Paul S. Ritch; Thomas E. Lad; Q. Scott Ringenberg; Joan H. Schiller; Robert R. Recker; Elisabeth Ryzen; Claude S. Arnaud; Michael D. Draper; Gordon J. Strewler; John M. Bennett; Joanne R. Carignan; Craig S. McCune; Raman Qazi; Patrick J. Byrne; Peder Charles; Claus Hasling; Leif Mosekilde; Ronald C. DeConti; Gregory R. Harper; John Horton; John C. Ruckdeschel; Alexander S. Spiers; Lee M. Zehngebot; David S. Ettinger; Martin D. Abeloff; Michael D. Green; Howard S. Hochster; Harold A. Harvey; Allan Lipton; Mary A. Simmonds; Subhash Kukreja; Daniel Shevrin; Michael R. McClung; Nancy Kane-Johnson; Eric S. Orwoll; Lawrence C. Panasci; Walter A. Brzezinski; Tom Anderson; Marjorie A. Vukelich; Al B. Benson; Thomas E. Davis; James K. Willson; Manuel Fernandez; Robert K. Rude

doi:10.1001/archinte.1991.00400030039007

Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study

Frederick R. Singer, Paul S. Ritch, Thomas E. Lad, Q. Scott Ringenberg, Joan H. Schiller, Robert R. Recker, Elisabeth Ryzen, Claude S. Arnaud, Michael D. Draper, Gordon J. Strewler, John M. Bennett, Joanne R. Carignan, Craig S. McCune, Raman Qazi, Patrick J. Byrne, Peder Charles, Claus Hasling, Leif Mosekilde, Ronald C. DeConti, Gregory R. HarperJohn Horton, John C. Ruckdeschel, Alexander S. Spiers, Lee M. Zehngebot, David S. Ettinger, Martin D. Abeloff, Michael D. Green, Howard S. Hochster, Harold A. Harvey, Allan Lipton, Mary A. Simmonds, Subhash Kukreja, Daniel Shevrin, Michael R. McClung, Nancy Kane-Johnson, Eric S. Orwoll, Lawrence C. Panasci, Walter A. Brzezinski, Tom Anderson, Marjorie A. Vukelich, Al B. Benson, Thomas E. Davis, James K. Willson, Manuel Fernandez, Robert K. Rude

Research output: Contribution to journal › Article › peer-review

92 Scopus citations

Abstract

In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

Original language	English (US)
Pages (from-to)	471-476
Number of pages	6
Journal	Archives of Internal Medicine
Volume	151
Issue number	3
DOIs	https://doi.org/10.1001/archinte.1991.00400030039007
State	Published - Mar 1991

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/archinte.1991.00400030039007

Cite this

Singer, F. R., Ritch, P. S., Lad, T. E., Ringenberg, Q. S., Schiller, J. H., Recker, R. R., Ryzen, E., Arnaud, C. S., Draper, M. D., Strewler, G. J., Bennett, J. M., Carignan, J. R., McCune, C. S., Qazi, R., Byrne, P. J., Charles, P., Hasling, C., Mosekilde, L., DeConti, R. C., ... Rude, R. K. (1991). Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study. Archives of Internal Medicine, 151(3), 471-476. https://doi.org/10.1001/archinte.1991.00400030039007

Singer, FR, Ritch, PS, Lad, TE, Ringenberg, QS, Schiller, JH, Recker, RR, Ryzen, E, Arnaud, CS, Draper, MD, Strewler, GJ, Bennett, JM, Carignan, JR, McCune, CS, Qazi, R, Byrne, PJ, Charles, P, Hasling, C, Mosekilde, L, DeConti, RC, Harper, GR, Horton, J, Ruckdeschel, JC, Spiers, AS, Zehngebot, LM, Ettinger, DS, Abeloff, MD, Green, MD, Hochster, HS, Harvey, HA, Lipton, A, Simmonds, MA, Kukreja, S, Shevrin, D, McClung, MR, Kane-Johnson, N, Orwoll, ES, Panasci, LC, Brzezinski, WA, Anderson, T, Vukelich, MA, Benson, AB, Davis, TE, Willson, JK, Fernandez, M & Rude, RK 1991, 'Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study', Archives of Internal Medicine, vol. 151, no. 3, pp. 471-476. https://doi.org/10.1001/archinte.1991.00400030039007

@article{364212227e3b4e4db16e6f210fc54617,

title = "Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study",

abstract = "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.",

author = "Singer, {Frederick R.} and Ritch, {Paul S.} and Lad, {Thomas E.} and Ringenberg, {Q. Scott} and Schiller, {Joan H.} and Recker, {Robert R.} and Elisabeth Ryzen and Arnaud, {Claude S.} and Draper, {Michael D.} and Strewler, {Gordon J.} and Bennett, {John M.} and Carignan, {Joanne R.} and McCune, {Craig S.} and Raman Qazi and Byrne, {Patrick J.} and Peder Charles and Claus Hasling and Leif Mosekilde and DeConti, {Ronald C.} and Harper, {Gregory R.} and John Horton and Ruckdeschel, {John C.} and Spiers, {Alexander S.} and Zehngebot, {Lee M.} and Ettinger, {David S.} and Abeloff, {Martin D.} and Green, {Michael D.} and Hochster, {Howard S.} and Harvey, {Harold A.} and Allan Lipton and Simmonds, {Mary A.} and Subhash Kukreja and Daniel Shevrin and McClung, {Michael R.} and Nancy Kane-Johnson and Orwoll, {Eric S.} and Panasci, {Lawrence C.} and Brzezinski, {Walter A.} and Tom Anderson and Vukelich, {Marjorie A.} and Benson, {Al B.} and Davis, {Thomas E.} and Willson, {James K.} and Manuel Fernandez and Rude, {Robert K.}",

year = "1991",

month = mar,

doi = "10.1001/archinte.1991.00400030039007",

language = "English (US)",

volume = "151",

pages = "471--476",

journal = "Archives of Internal Medicine",

issn = "0003-9926",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate

T2 - A Controlled, Multicenter Study

AU - Singer, Frederick R.

AU - Ritch, Paul S.

AU - Lad, Thomas E.

AU - Ringenberg, Q. Scott

AU - Schiller, Joan H.

AU - Recker, Robert R.

AU - Ryzen, Elisabeth

AU - Arnaud, Claude S.

AU - Draper, Michael D.

AU - Strewler, Gordon J.

AU - Bennett, John M.

AU - Carignan, Joanne R.

AU - McCune, Craig S.

AU - Qazi, Raman

AU - Byrne, Patrick J.

AU - Charles, Peder

AU - Hasling, Claus

AU - Mosekilde, Leif

AU - DeConti, Ronald C.

AU - Harper, Gregory R.

AU - Horton, John

AU - Ruckdeschel, John C.

AU - Spiers, Alexander S.

AU - Zehngebot, Lee M.

AU - Ettinger, David S.

AU - Abeloff, Martin D.

AU - Green, Michael D.

AU - Hochster, Howard S.

AU - Harvey, Harold A.

AU - Lipton, Allan

AU - Simmonds, Mary A.

AU - Kukreja, Subhash

AU - Shevrin, Daniel

AU - McClung, Michael R.

AU - Kane-Johnson, Nancy

AU - Orwoll, Eric S.

AU - Panasci, Lawrence C.

AU - Brzezinski, Walter A.

AU - Anderson, Tom

AU - Vukelich, Marjorie A.

AU - Benson, Al B.

AU - Davis, Thomas E.

AU - Willson, James K.

AU - Fernandez, Manuel

AU - Rude, Robert K.

PY - 1991/3

Y1 - 1991/3

N2 - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

AB - In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days. Patients also received up to 3.25 L of saline daily during the treatment period. Of 157 patients for whom data could be evaluated for efficacy, 63% (72/114) of etidronate-treated and 33% (14/43) of saline-treated patients had a normalization of total serum calcium levels. When serum calcium levels were adjusted for albumin (147 assessable patients), 24% of the etidronate- and 7% of the saline-treated patients responded to treatment. No serious side effects or treatmentrelated deaths occurred. When accompanied by adequate hydration and diuresis, intravenous etidronate was safe and more effective than hydration and diuresis alone in controlling hypercalcemia of malignancy.

UR - http://www.scopus.com/inward/record.url?scp=0025974180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025974180&partnerID=8YFLogxK

U2 - 10.1001/archinte.1991.00400030039007

DO - 10.1001/archinte.1991.00400030039007

M3 - Article

C2 - 1900410

AN - SCOPUS:0025974180

SN - 0003-9926

VL - 151

SP - 471

EP - 476

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

IS - 3

ER -

Treatment of Hypercalcemia of Malignancy With Intravenous Etidronate: A Controlled, Multicenter Study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this